# Ongoing Clinical Trials in Ovarian Tumours
## Medical Student Notes - OBG (2026)

---

## QUICK OVERVIEW
- **612 recruiting trials** actively enrolling patients (August 2026)
- **4 major therapeutic approaches:** ADCs, PARP inhibitors, checkpoint immunotherapy, emerging mechanisms
- **Key principle:** Moving from single-agent to combination strategies

---

## 1. ANTIBODY-DRUG CONJUGATES (ADCs) - 34 TRIALS

### Mechanism
- Antibody targets specific tumour antigen
- Cytotoxic payload delivered directly to cancer cells
- Reduces systemic toxicity vs. conventional chemotherapy

### Active Agents

| Drug | Target | Status | Notes |
|------|--------|--------|-------|
| **Mirvetuximab soravtansine** | Folate receptor-α (FRα) | Standard of care | Most established; ongoing combination trials |
| **AZD5335** | FRα | Development | Next-gen FRα-ADC |
| **Rina-S** | TROP2 | Phase development | TROP2-directed |
| **Sacituzumab tirumotecan** | TROP2 | Phase 3 | Non-HRD patients (MK-2870-021) |
| **T-DXd** | HER2 | Active trials | HER2-low/negative disease |
| **Raludotatug deruxtecan** | Unknown target | Development | Emerging ADC |
| **BG-C9074** | B7H4 | Phase 1a/1b | Monotherapy + tislelizumab (PD-L1i) |

### Key Point for Students
ADCs are transforming ovarian cancer therapy because they deliver toxins specifically to tumour cells while sparing healthy tissue.

---

## 2. PARP INHIBITORS - 58 TRIALS

### Background
- Block poly-ADP-ribose polymerase (DNA repair enzyme)
- Approved for BRCA-mutated and homologous recombination deficiency (HRD) patients
- **2022 regulatory action:** Olaparib, niraparib, rucaparib lost approval for 3rd-line therapy (↑ adverse events)

### Current Trial Focus Areas

**Non-HRD Combinations**
- Testing PARP inhibitors in biomarker-unselected populations
- Rationale: May work in wider patient subset when combined

**PARP + Angiogenesis Inhibitors**
- PARP inhibitor + bevacizumab + durvalumab (triplet)
- Data: Longer PFS vs. bevacizumab alone in BRCA wild-type patients

**PARP Re-challenge**
- Re-treating platinum-resistant patients after initial PARP exposure
- Investigates optimal dosing and timing

**PARP + Checkpoint Inhibitors (CPIs)**
- Based on synthetic lethality theory
- PARP inhibition triggers DNA damage → immunogenic cell death → enhances CPI response

### Key Agents
- Olaparib, niraparib (ongoing trials)
- ETX-19477 (PARG inhibitor, not PARP) - Phase 2 for BRCA-mutated ovarian cancer

### Key Point for Students
PARP trials have shifted from maintenance monotherapy toward combination strategies to overcome resistance.

---

## 3. IMMUNE CHECKPOINT INHIBITORS (CPIs) - 48 TRIALS

### Current Evidence (Systematic Review 2025)

**Disappointing Monotherapy Results**
- Single-agent PD-L1 inhibitors: **NOT effective** in newly diagnosed ovarian cancer
- CPIs alone: **NOT effective** in platinum-sensitive or platinum-resistant disease
- **Reason:** Ovarian cancer relatively immunologically cold compared to melanoma/lung cancer

**Successful Combinations (limited data)**
- Triplet: Bevacizumab + olaparib + durvalumab → longer PFS in non-BRCA-mutated patients

### Active Trial Approaches

| Approach | Rationale | Status |
|----------|-----------|--------|
| **PD-1/PD-L1 + bevacizumab** | Anti-angiogenesis + immune activation | 48 trials active |
| **CTLA-4 + PD-1 dual inhibition** | Broader T-cell activation | Under investigation |
| **CPI + PARP inhibitor** | Synthetic lethality + immunogenicity | Ongoing Phase 2/3 |
| **CPI + ADCs** | Targeted toxicity + immune activation | Early trials |

### Key Point for Students
CPIs work poorly alone in ovarian cancer but may improve outcomes when combined with other modalities (angiogenesis inhibitors, PARP inhibitors, ADCs).

---

## 4. EMERGING MECHANISMS - MULTIPLE TRIALS

### Bispecific Antibodies

**Ubamatamab**
- Target: Unknown (investigational bispecific)
- Phase 2 for platinum-resistant ovarian cancer
- Monotherapy and combinations under study

**PHST001 (Pheast Therapeutics)**
- Target: CD24 (macrophage checkpoint)
- Mechanism: Blocks "don't eat me" signal on cancer cells
- Phase 1 in solid tumours including ovarian cancer

**BG-C9074 (mentioned above)**
- Target: B7H4
- Phase 1a/1b ± tislelizumab (PD-L1 inhibitor)

### DNA Repair Pathway Inhibitors

**PARG Inhibitors (e.g., ETX-19477)**
- Blocks PARG (DNA repair cofactor)
- FDA Fast Track designation for BRCA-mutated breast cancer
- Phase 2 monotherapy cohorts: BRCA-mutated ovarian cancer

**Cyclin E1 Inhibitors (for platinum-resistant disease)**
- INCB123667, azenosertib
- Target early-onset cell-cycle drivers

### Oncolytic Virus Immunotherapy
- Early-stage trials combining viral vectors with immune activation
- Mechanism: Viral lysis + recruitment of immune cells

### Key Point for Students
New mechanisms explore different vulnerabilities: macrophage dysfunction (BG-C9074, PHST001), alternative DNA repair pathways (PARG), and cell-cycle dysregulation (Cyclin E1i).

---

## 5. PHASE I TRIAL DATA (2012-2023) - WHAT WORKS?

### Systematic Review of 78 Phase I Trials

**Three Treatment Categories:**

| Strategy | Frequency | Toxicity | Response Rate | Clinical Benefit | Median PFS |
|----------|-----------|----------|---------------|-----------------|-----------|
| **Chemotherapy only (CO)** | 17.9% | Highest ↑↑ | 11.5% | 40% | 5.9 mo |
| **Chemo + targeted/immuno (CNC)** | 53.8% | Moderate | 32.2% | 62% | 6.45 mo |
| **Chemotherapy-free (CF)** | 28.2% | Lowest ↓↓ | 25.5% | 52% | 4.85 mo |

### Conclusions
- **CNC (combination) regimens outperform** both CO and CF on efficacy
- **CF strategies** have best safety profile but lower efficacy
- **Trend:** Moving away from chemotherapy-only approaches

### Key Point for Students
The future is combination therapy (CNC) - balancing efficacy with tolerability.

---

## 6. TRIAL-SPECIFIC UPDATES (August 2026)

### Allarity Therapeutics - Stenoparib (PARP-like inhibitor)
- Phase 2: Advanced ovarian cancer + SCLC
- Companion diagnostic (DRP - Drug Response Predictor): CLIA certification obtained
- Manufacturing completed; Phase 3 readiness achieved Q2 2026

### 858 Therapeutics - ETX-19477 (PARG Inhibitor)
- FDA Fast Track designation (BRCA-mutated breast cancer)
- Phase 1/2 trial: Multiple U.S. sites (NCT06395519)
- Phase 2 cohorts enrolling: BRCA-mutated ovarian cancer

---

## 7. KEY CLINICAL TRIAL PRINCIPLES FOR STUDENTS

### Trial Participation Benefits Survival
- Newly diagnosed advanced ovarian cancer patients in trials: **improved OS vs. non-trial patients**
- Emphasize trial discussion in counselling

### Patient Selection Biomarkers (Critical)
- **BRCA1/2 status** - Predicts PARP benefit
- **HRD (Homologous Recombination Deficiency)** - PARP/ADC response
- **PD-L1 expression** - CPI response (modest predictor)
- **FRα expression** - Mirvetuximab benefit
- **HER2 status** - T-DXd benefit (emerging)

### Platinum Sensitivity Status
- Platinum-sensitive: Better trial outcomes
- Platinum-resistant: Worse outcomes, needs novel approaches (ADCs, bispecifics, CDK inhibitors)

### Histology Matters
- **High-grade serous (HGSOC):** Most common; most trials enroll this
- **Clear cell:** CPIs + CTLA-4 combinations under investigation
- **Endometrioid:** Limited trial data; often HRD+

---

## 8. COMMON MS EXAM QUESTIONS

**Q: Why are ADCs better than conventional chemotherapy?**
A: They deliver cytotoxic agents specifically to tumour cells (via antibody targeting), reducing systemic exposure and toxicity.

**Q: Why did PARP inhibitor approvals get revoked?**
A: Olaparib, niraparib, rucaparib lost 3rd-line approval (2022) due to unacceptable adverse events in recurrent disease.

**Q: Why are CPIs not effective in ovarian cancer alone?**
A: Ovarian cancer is immunologically "cold" with low PD-L1 expression and limited tumour-infiltrating lymphocytes. CPIs require an active immune environment.

**Q: What is the rationale for PARP + CPI combination?**
A: PARP inhibition causes DNA damage → triggers immunogenic cell death → enhances CPI response (synthetic lethality).

**Q: Which ADC is standard of care?**
A: Mirvetuximab soravtansine (FRα-targeting ADC).

---

## 9. STUDY SUMMARY TABLE

| Trial Type | # Active | Mechanism | Best Results | Limitations |
|-----------|---------|-----------|--------------|------------|
| **ADCs** | 34 | Targeted toxin delivery | Mirvetuximab standard care | Single-agent plateau; combinations ongoing |
| **PARP inhibitors** | 58 | DNA repair inhibition | CNC > CO alone | Resistance develops; benefit limited to HRD+ |
| **CPIs** | 48 | Immune checkpoint blockade | Triplet maintenance (bevacizumab + PARP + CPI) | Poor monotherapy efficacy; biomarker selection needed |
| **Emerging** | Multiple | Bispecifics, PARG i, Cyclin E i | Early data promising | Too early for clinical practice |

---

## 10. CLINICAL TAKEAWAY FOR STUDENTS

### "The Combination Era"
Ovarian cancer trials have moved from single-agent monotherapy to **rational combination strategies**:
- Cytotoxic + targeted (ADC + CPI)
- Targeted + targeted (PARP + bevacizumab)
- Targeted + immune (PARP + CPI)
- Multi-modal (bevacizumab + PARP + CPI triplet)

### Why?
- Single agents hit one vulnerability
- Cancers adapt → resistance
- Combinations target multiple pathways simultaneously

### For Patient Counselling
- Trial participation improves outcomes
- Multiple treatment options now available beyond standard chemotherapy
- Biomarker testing (BRCA, HRD, PD-L1) increasingly important
- Discuss trial eligibility early in disease course

---

## References
- Pavone G, et al. A systematic review of phase I trials in patients with ovarian cancer. *Cancer Treat Rev*. 2025. [Systematic Review]
- Bogani G, et al. Incorporating immune checkpoint inhibitors in epithelial ovarian cancer. *Gynecol Oncol*. 2025. [Systematic Review]
- Xiao F, et al. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer. *J Transl Med*. 2024.
- ClinTrialFinder. 612 Ovarian Cancer Clinical Trials Recruiting Now. August 2026.

---

**Last Updated:** August 26, 2026  
**Format:** Medical Student Study Notes - OBG  
**Target:** MS3-MS4 / Resident preparation

# Oocyte Cryopreservation
## Medical Student Notes - OBG (2026)

---

## QUICK OVERVIEW

**What is it?**
- Freezing unfertilized eggs (oocytes) to preserve fertility
- Used for delayed childbearing, medical emergencies, or fertility preservation before gonadotoxic treatment

**Current Status:**
- **Vitrification is standard technique** (rapid freezing, minimal ice crystal formation)
- Oocyte survival after thawing: ~78.5% (95% CI: 74-83%)
- Live birth rate per patient (planned cryopreservation): 28% overall
- Age at preservation is **critical determinant** of success

**Key Point for Students:** Oocyte cryopreservation is now considered **effective and safe**, but outcomes depend heavily on age, oocyte quality, and number retrieved.

---

## 1. INDICATIONS FOR OOCYTE CRYOPRESERVATION

### Medical/Therapeutic Indications
- **Chemotherapy/radiotherapy** - Before gonadotoxic cancer treatment
- **Hematologic malignancies** - Before chemotherapy (leukemia, lymphoma, myeloma)
- **Autoimmune diseases** - Before immunosuppressive therapy
- **Other gonadotoxic medications** - Certain rheumatologic or systemic treatments
- **Endometriosis** - Preventive fertility preservation before surgery
- **Genetic counselling** - Relatives of cancer patients; preventive approach

### Elective/Social Indications
- **Planned/deferred motherhood** - Women wanting to delay childbearing
- **Age-related fertility decline prevention** - "Fertility insurance" for older reproductive age
- **Occupational/life circumstances** - Delayed family planning due to career, education, relationship status
- **Single status** - Women without current partner who want biological children later

### Indications with Limited Evidence
- **Endometriosis** - Data insufficient to recommend routine preventive cryopreservation (see below)
- **Recurrent pregnancy loss** - Not standard indication; needs individualized counselling

---

## 2. CRYOPRESERVATION TECHNIQUES

### A. VITRIFICATION (Current Standard)

**Mechanism:**
- Ultra-rapid freezing (cooling rate ~20,000°C/min)
- Intracellular water converts to glass-like solid state (amorphous)
- **Minimal ice crystal formation** = less mechanical cell damage
- Uses high concentration cryoprotectants (ethylene glycol, DMSO)

**Advantages:**
- Highest survival rates post-thaw (78.5%)
- Faster procedure (~15-30 minutes)
- Better oocyte morphology post-thaw
- Recommended for routine use (ASRM, ESHRE)

**Disadvantages:**
- Requires specialized equipment
- High cryoprotectant concentrations → potential toxicity
- Technique-dependent (operator skill critical)

**Survival Rate Post-Thaw:**
- Overall: 78.5% (95% CI: 74-83%)
- Comparable to slow-freezing in meta-analysis (RR 0.96, p=0.52)

---

### B. SLOW/CONVENTIONAL CRYOPRESERVATION

**Mechanism:**
- Gradual controlled-rate freezing (~1-2°C/min down to -90°C)
- External ice crystals form first; water gradually leaves cells
- Then plunged into liquid nitrogen

**Advantages:**
- More time for water extrusion
- Less cryoprotectant toxicity
- Established technique; more experience in some centres

**Disadvantages:**
- Slower procedure; requires programmable freezer
- More ice crystal formation inside cells
- Comparable outcomes to vitrification (no statistical difference)

---

### C. COMPARISON: VITRIFICATION vs. SLOW FREEZING

**Meta-Analysis Data (2025)** - 18 studies:

| Parameter | Vitrification | Slow Freezing | Difference | Evidence |
|-----------|--------------|---------------|-----------|----------|
| **Follicular viability** | Similar | Similar | RR 0.96 (p=0.52) | No difference |
| **Intact primordial follicles** | Similar | Similar | RR 1.01 (p=0.78) | No difference |
| **DNA fragmentation** | Similar | Similar | RR 1.20 (p=0.15) | No difference |
| **Stromal cell integrity** | Similar | Similar | RR 0.58 (p=0.30) | No difference |

**Clinical Bottom Line:** Both techniques provide comparable histological outcomes. **Vitrification preferred** due to speed, ease of use, and consistency of results.

---

## 3. TECHNIQUE DETAILS: VITRIFICATION PROCESS

### Step-by-Step Procedure (Oocyte)

1. **Oocyte selection**
   - Metaphase II (MII) oocytes only
   - First polar body visible = mature, ready to fertilize after thaw

2. **Cryoprotectant loading** (equilibration)
   - Gradual exposure to cryoprotectant solution (ethylene glycol + DMSO)
   - Duration: 10-15 minutes
   - Temperature: Room temperature or 37°C
   - Allows intracellular water replacement with cryoprotectant

3. **Final cryoprotectant solution**
   - High concentration (often 30-40% combined cryoprotectants)
   - Rapid loading into vitrification device (cryovial, straw, or proprietary system)
   - Duration: <1 minute to minimize osmotic damage

4. **Vitrification (freezing)**
   - Direct immersion into liquid nitrogen (-196°C)
   - Cooling rate: ~20,000°C/min
   - Oocyte converts to solid glass-like state

5. **Storage**
   - In liquid nitrogen (-196°C) or nitrogen vapor (-150°C)
   - Indefinite storage (no time limit established)

6. **Thawing (reversal)**
   - Remove from liquid nitrogen
   - Rapid warming in warm solution
   - Cryoprotectant gradual removal (dilution)
   - Osmotic rehydration of cell

### Key Point for Students
The entire vitrification process takes **<15 minutes**, making it fast and practical for clinical use.

---

## 4. OUTCOMES DATA

### A. PLANNED OOCYTE CRYOPRESERVATION (POC) - SOCIAL FREEZING

**Systematic Review & Meta-Analysis (2024)** - 10 studies, 8,750 women:

**Primary Outcome: Live Birth Rate per Patient**
- **Overall:** 28% (95% CI: 24-33%)
- **447 total live births reported**

**Age-Stratified Success Rates:**
| Age at Cryopreservation | Live Birth Rate | Notes |
|------------------------|-----------------|-------|
| **≤35 years old** | **52%** (95% CI: 41-63%) | Best prognosis |
| **35-40 years old** | 28% (implied from overall) | Moderate |
| **≥40 years old** | **19%** (95% CI: 13-29%) | Significantly lower |

**Secondary Outcomes:**
- **Oocyte survival rate (post-thaw):** 78.5% (95% CI: 74-83%)
- **Return to thaw rate:** 11.1% (±4.7%)
  - Only ~1 in 9 women return to use their frozen oocytes
  - Mean age at cryopreservation for women who returned: 38.1 years
  - Mean oocytes retrieved: 12.6 per woman
  - Cryopreservation age for returners: 38.1 years (slightly older than mean)

**Number of Oocytes Needed for 1 Live Birth:**
- Varies by age at cryopreservation
- General estimate: 8-15 mature (MII) oocytes recommended for reasonable success
- Older age = need more oocytes (due to increased aneuploidy)

---

### B. OVARIAN TISSUE CRYOPRESERVATION (for reference)

**Note:** Primarily for young cancer patients; distinct from oocyte freezing but relevant context.

**Tissue Viability Outcomes:**
- Follicular viability: ~75-90% post-thaw (variable)
- Can be stored for years until reproductive readiness
- Allows multiple thaw cycles for oocyte retrieval
- Still largely experimental; <50 live births worldwide

---

## 5. SPECIFIC CLINICAL SCENARIOS

### A. OOCYTE CRYOPRESERVATION IN ENDOMETRIOSIS

**Systematic Review (2025)** - 10 observational studies:

**Findings:**
- **Oocyte retrieval decreased with increasing age** - expected, not endometriosis-specific
- **Previous endometriosis surgery → reduced oocyte numbers** - significant finding
- **Type of endometriosis (superficial/deep), laterality, or endometrioma size did NOT predict** oocyte retrieval success
- **Oocyte maturation rate NOT affected** by history of endometriosis surgery

**Major Limitation:**
- **Substantial lack of follow-up data** on use of cryopreserved oocytes
- No adequate data on fertilization, implantation, pregnancy, or live birth rates
- Cannot recommend routine preventive cryopreservation for all endometriosis patients

**Clinical Bottom Line for Students:**
Preventive oocyte cryopreservation in endometriosis is **not routinely recommended** due to insufficient outcome data, but may be considered for women with:
- Advanced endometriosis (stage III-IV)
- Planned surgery likely to reduce ovarian reserve
- Already considering fertility preservation for other reasons

---

### B. OOCYTE CRYOPRESERVATION IN HEMATOLOGIC MALIGNANCIES

**Systematic Review & Meta-Analysis (2025):**

**Context:**
- Women with hematologic cancers (leukemia, lymphoma, myeloma) face chemotherapy toxicity to ovarian reserve
- Need rapid fertility preservation before treatment initiation

**Key Considerations:**
- **Time constraint:** Chemotherapy may start within days; oocyte retrieval requires 10-14 days
- **Ovarian stimulation safety:** Estrogen concerns in hormone-sensitive malignancies (some leukemias, lymphomas)
- **Oocyte quality:** May be affected by underlying malignancy or imminent chemotherapy

**Outcomes:**
- Data limited but increasingly available
- Similar survival rates to general population (78-80% post-thaw)
- Live birth outcomes variable; depends on oocyte quantity/quality at retrieval

---

## 6. PATIENT COUNSELLING POINTS

### Before Cryopreservation

**Success Rates (be honest):**
- "Of every 100 women who freeze oocytes, about 28 will have a live birth if they use them"
- "Success depends heavily on your age NOW - freezing at 35 gives much better chances (52%) than freezing at 40 (19%)"
- "Freezing slows down but does not stop egg aging. Younger is better."

**Number of Oocytes:**
- "We aim to retrieve 8-15 mature eggs for reasonable success chances"
- "Not all eggs will survive thawing (expect ~78% survival)"
- "Some eggs won't fertilize even after thawing"

**Realistic Outcomes:**
- "Even with freezing, pregnancy is not guaranteed"
- "If you do use frozen oocytes, the miscarriage rate is similar to your age at freezing, not your current age"
- "Return rate is low - only 11% of women who freeze oocytes ever use them"

**Costs & Logistics:**
- "Freezing is one cost; storage is ongoing; thawing and IVF is another cost"
- "Storage can continue indefinitely if desired"
- "Plan for future use - insurance usually doesn't cover elective freezing"

### After Cryopreservation

**What to expect:**
- "Your oocytes are stored safely in liquid nitrogen"
- "When you're ready (weeks, years, or decades later), we can thaw them"
- "Thawing takes 30-60 minutes"
- "We'll fertilize them via IVF and monitor for embryo development"

**Complications are rare:**
- Oocyte loss during storage: <1% (if proper protocols followed)
- Thaw survival: 78.5% expected
- Contamination: <0.1% in accredited centres

---

## 7. COMPLICATIONS & RISKS

### A. OVARIAN STIMULATION RISKS
- **Ovarian hyperstimulation syndrome (OHSS):** 1-2% moderate, 0.1-0.2% severe
- **Infection at retrieval:** <0.1%
- **Bleeding at retrieval:** <0.5% clinically significant
- **Pelvic injury:** <0.1%

### B. CRYOPRESERVATION-RELATED COMPLICATIONS
- **Oocyte damage during freezing:** 15-22% loss (reflected in 78% survival rate)
- **Osmotic damage:** Rare if protocols followed
- **Contamination/infection:** <0.1% in accredited centres
- **Storage failure:** <1% with proper tank maintenance
- **Equipment failure:** Accredited centres have backup systems

### C. LONG-TERM CONSIDERATIONS
- **Chromosomal abnormality risk:** Related to AGE AT FREEZING, not duration of storage
  - Woman frozen at 40: miscarriage risk = age 40 risk (~30%), not age 45 risk
  - This is an advantage of early freezing
- **Genetic imprinting:** No evidence of abnormal imprinting after oocyte freezing
- **Developmental outcomes:** Children born from thawed oocytes show normal development (long-term data 15+ years)

---

## 8. VIABILITY OF FROZEN STORAGE

### Storage Duration
- **Indefinite** - No established time limit for safe storage
- Animal studies suggest oocytes viable for decades (mouse studies >10 years)
- Human data: Pregnancies achieved after 13+ years storage
- Current longest-stored human oocyte: ~25 years (no adverse outcomes)

### Storage Conditions
- **Liquid nitrogen:** -196°C (most common)
- **Nitrogen vapor:** -150°C (alternative, slightly safer but less commonly used)
- **Tank maintenance:** Critical; regular checks for nitrogen levels, contamination

### Thawing Anytime?
- Yes, can thaw oocytes years or decades after freezing
- No apparent degradation with prolonged storage at proper temperature
- Pregnancy risk mainly related to egg age at time of freezing, not storage duration

---

## 9. OUTCOMES OF OOCYTE CRYOPRESERVATION: TAKE-HOME DATA

### Live Birth Rates
| Setting | Live Birth Rate | Key Factor |
|---------|-----------------|-----------|
| **Age ≤35 at freezing** | 52% | Young oocytes = better quality |
| **Age 35-40 at freezing** | 28% (approx) | Moderate decline |
| **Age ≥40 at freezing** | 19% | Significant decline |
| **Overall average** | 28% | Depends on age distribution |

### Oocyte Survival
- **Post-thaw survival:** 78.5%
- **Fertilization rate (post-thaw):** 50-80% (similar to fresh)
- **Cleavage rate (Day 3):** 60-80%
- **Blastulation rate:** 40-60%
- **Implantation rate:** Age-dependent (similar to age at freezing)

---

## 10. ETHICAL & COUNSELLING CONSIDERATIONS

### Regulatory Status
- **ASRM (American Society for Reproductive Medicine):** Oocyte cryopreservation no longer considered experimental (2012, reaffirmed 2023)
- **ESHRE (European Society of Human Reproduction & Embryology):** Recommended as standard fertility preservation method
- **FIGO (International Federation of Gynecology & Obstetrics):** Endorses for medical and elective indications

### Informed Consent Elements
1. Limited success rates (especially with age ≥40)
2. Multiple procedures: retrieval now, thawing later, embryo transfer
3. Multiple costs (retrieval, storage, thawing, IVF)
4. Unknown long-term psychological impact of unused oocytes
5. Return rate only 11% - most women don't use their oocytes
6. Storage can continue indefinitely but requires ongoing payment
7. Alternative options: adoption, child-free life, use of donor oocytes

### Counselling for "Fertility Insurance"
- Set realistic expectations
- Emphasize age matters: freeze early if considering it
- Discuss psychological burden of unused oocytes
- Address false hope (freezing doesn't guarantee pregnancy)
- Explore alternative family-building options

---

## 11. MEDICAL INDICATIONS: PRIORITY FOR COUNSELLING

### MUST COUNSEL / URGENT INDICATION
- **Upcoming chemotherapy/radiotherapy** → Refer urgently (days matter)
- **Hematologic malignancy before treatment**
- **Autoimmune disease before immunosuppression**
- **Genetic risk for early menopause** (family history of premature ovarian insufficiency)

### SHOULD COUNSEL / CONSIDER INDICATION
- **Age >35 considering delayed motherhood** - Discuss success rates by age
- **Endometriosis with planned surgery** - Limited data but reasonable option for some
- **Family history of cancer** - Preventive approach for high-risk individuals

### DON'T ROUTINELY OFFER
- **Routine fertility preservation for all cancer patients** - Patient choice; not all want it
- **Endometriosis without other risk factors** - Insufficient evidence
- **Unproven indications** - e.g., recurrent pregnancy loss, subfertility (use IVF with fresh oocytes instead)

---

## 12. MS EXAM HIGH-YIELD FACTS

**Q: What is the survival rate of oocytes after thawing?**
A: 78.5% (95% CI: 74-83%)

**Q: What is the live birth rate for planned oocyte cryopreservation?**
A: 28% overall; 52% for age ≤35 at freezing; 19% for age ≥40 at freezing

**Q: What is the preferred cryopreservation technique?**
A: Vitrification (ultra-rapid freezing) - comparable outcomes to slow freezing but faster and more practical

**Q: Does oocyte cryopreservation increase chromosomal abnormality risk?**
A: No. Risk is related to age AT FREEZING, not duration of storage. Oocytes frozen at age 40 retain age 40 aneuploidy risk.

**Q: What percentage of women who freeze oocytes actually use them?**
A: Only 11% (±4.7%) return to thaw and use their oocytes

**Q: Is there a time limit for oocyte storage?**
A: No established limit. Animal and human data support viability for decades at -196°C

**Q: What is the main indication limiting routine oocyte cryopreservation in endometriosis?**
A: Lack of follow-up data on pregnancy and live birth outcomes

**Q: Which age group has the best live birth rate with planned oocyte cryopreservation?**
A: Women ≤35 years old (52% live birth rate)

**Q: What is the recommended number of mature oocytes for reasonable success with cryopreservation?**
A: 8-15 metaphase II oocytes (MII)

**Q: Name three medical indications for oocyte cryopreservation:**
A: (1) Chemotherapy before cancer treatment, (2) Hematologic malignancies before treatment, (3) Autoimmune disease before immunosuppression

---

## 13. COMPARISON TABLE: VITRIFICATION vs. SLOW FREEZING

| Feature | Vitrification | Slow Freezing |
|---------|---------------|---------------|
| **Freezing rate** | ~20,000°C/min (ultra-rapid) | 1-2°C/min (controlled) |
| **Ice crystal formation** | Minimal (glass-like state) | Moderate (external then internal) |
| **Cryoprotectant concentration** | High (30-40%) | Lower (5-10%) |
| **Time to freeze** | 15-30 minutes | 30-60 minutes |
| **Equipment** | Specialized device needed | Programmable freezer |
| **Operator skill required** | High | Moderate |
| **Oocyte survival post-thaw** | 78% | 78% (no difference) |
| **Follicle integrity** | Similar | Similar |
| **Current status** | STANDARD (preferred) | Alternative; comparable |
| **Evidence quality** | High; >1000 studies | High; extensive data |

---

## 14. SUMMARY FOR CLINICAL PRACTICE

### When to Offer
1. **Medical urgency:** Before gonadotoxic therapy (cancer, immunosuppression)
2. **Age consideration:** Women ≤40 considering fertility preservation
3. **Specific conditions:** Advanced endometriosis, genetic risk, occupational hazards
4. **Patient request:** Woman explicitly wants to delay motherhood and preserve fertility

### When to Counsel (realistic expectations)
- Success depends heavily on age at freezing
- Only 28% overall live birth rate (52% if frozen ≤35 years)
- Most women (89%) never return to use their oocytes
- Costs substantial and ongoing
- Safe storage indefinite, but viability depends on age at freezing

### When NOT to Offer
- Routine offer to all young women (resource-intensive; low uptake)
- Unproven indications (subfertility, recurrent pregnancy loss)
- Women with religious/ethical objections to freezing
- Cases where immediate natural conception is feasible

---

## REFERENCES

1. Kong Q, et al. Comparison of ovarian tissue cryopreservation by conventional slow cryopreservation and vitrification. *J Ovarian Res*. 2025;18:33. [Systematic Review/Meta-Analysis]

2. Nicolì P, et al. Oocyte cryopreservation for patients with endometriosis: where are we now? *Reprod Biomed Online*. 2025;51:104839. [Systematic Review]

3. Hirsch A, et al. Planned oocyte cryopreservation: a systematic review and meta-regression analysis. *Hum Reprod Update*. 2024;30:dmae009. [Systematic Review/Meta-Analysis]

4. Dufour S, et al. Oocyte Cryopreservation Outcomes in Women With Hematological Malignancies Undergoing Chemotherapy. *J Obstet Gynaecol Can*. 2025;53:102824. [Systematic Review/Meta-Analysis]

5. Behl S, et al. Vitrification versus slow freezing of human ovarian tissue: a systematic review and meta-analysis. *J Assist Reprod Genet*. 2023;40:47-58. [Systematic Review/Meta-Analysis]

---

**Last Updated:** August 26, 2026  
**Format:** Medical Student Study Notes - OBG  
**Target Audience:** MS3-MS4 / OBG Residents / Board Exam Prep  
**Evidence Base:** Systematic reviews, meta-analyses, and clinical guidelines (2023-2025)

# Oocyte Cryopreservation
## 7-Mark Exam Answer Format

---

## QUESTION: What is oocyte cryopreservation? Discuss its indications, techniques, and outcomes.
**[7 Marks]**

---

## ANSWER STRUCTURE (7 marks = 1 mark per point)

### 1. DEFINITION & CONCEPT (1 mark)

**Definition:**
Oocyte cryopreservation is the freezing and storage of unfertilized mature eggs (metaphase II oocytes) at ultra-low temperatures (-196°C in liquid nitrogen) to preserve fertility for future use. It allows women to delay motherhood while maintaining reproductive potential.

**Key Point:** The oocytes are arrested in metaphase II and can be stored indefinitely until thawed for IVF.

---

### 2. INDICATIONS (1 mark)

**Medical Indications:**
- Chemotherapy/radiotherapy before cancer treatment
- Hematologic malignancies (leukemia, lymphoma) before chemotherapy
- Autoimmune diseases before immunosuppressive therapy
- Endometriosis before surgery (limited evidence)

**Elective/Social Indications:**
- Planned deferred motherhood (fertility insurance)
- Age-related fertility decline prevention
- Career/occupational reasons
- Single women wanting biological children later

**Key Point:** Medical indications are urgent and time-sensitive; elective indications require realistic counselling about success rates.

---

### 3. CRYOPRESERVATION TECHNIQUES (1.5 marks)

**A. VITRIFICATION (Standard Technique):**
- Ultra-rapid freezing (~20,000°C/min)
- Intracellular water converts to glass-like solid state
- Minimal ice crystal formation → less cell damage
- Uses high-concentration cryoprotectants (ethylene glycol, DMSO)
- Time: <15 minutes

**B. SLOW/CONVENTIONAL FREEZING:**
- Gradual controlled freezing (1-2°C/min)
- Water gradually leaves cells before plunging into liquid nitrogen
- More established but slower technique
- Uses lower cryoprotectant concentrations

**Comparison:**
Both techniques have **comparable outcomes** (meta-analysis 2025):
- Oocyte survival: ~78% (no statistical difference)
- Follicle integrity: Similar
- **Vitrification now preferred** (faster, more practical, reproducible)

**Key Point:** Vitrification is the gold standard; outcomes are equivalent between techniques.

---

### 4. OUTCOMES - OOCYTE SURVIVAL (1 mark)

**Post-Thaw Survival:**
- Overall oocyte survival rate: **78.5%** (95% CI: 74-83%)
- Fertilization rate (post-thaw): 50-80% (similar to fresh oocytes)
- Cleavage rate (Day 3): 60-80%
- Implantation rate: Age-dependent

**Live Birth Rates (Planned Cryopreservation):**
- **Overall:** 28% per patient
- **Age ≤35 years at freezing:** 52% (best prognosis)
- **Age 35-40 years:** ~28% (moderate)
- **Age ≥40 years:** 19% (significantly lower)

**Key Point:** Age at time of freezing is the most critical determinant of success; younger oocytes have better outcomes.

---

### 5. CLINICAL CONSIDERATIONS (1 mark)

**Return to Use:**
- Only **11%** of women who freeze oocytes ever return to use them
- Mean cryopreserved oocytes: 12.6 per woman
- Those who returned had mean age at cryopreservation: 38.1 years

**Storage Duration:**
- **Indefinite storage** - No time limit established
- Oocytes viable for decades at -196°C
- Risk of chromosomal abnormality depends on **age at freezing, NOT duration of storage**

**Number of Oocytes Needed:**
- Recommend 8-15 mature (metaphase II) oocytes for reasonable success
- Older women need more oocytes (due to increased aneuploidy)

**Key Point:** Most women don't use their frozen oocytes; storage is safe but expensive and ongoing.

---

### 6. ADVANTAGES & DISADVANTAGES (1 mark)

**Advantages:**
- Allows delay of motherhood without age-related decline
- Safe and effective (not experimental since 2012)
- Indefinite storage possible
- Preserves reproductive autonomy
- 78% survival rate post-thaw
- No increased birth defects compared to natural conception

**Disadvantages:**
- Low overall success rate (28%)
- Age-dependent effectiveness (poor outcomes ≥40 years)
- Expensive procedure (retrieval, storage, thawing, IVF)
- Only 11% return to use oocytes (psychological burden of unused eggs)
- Requires ovarian stimulation (small risk of OHSS <2%)
- Not covered by insurance in most countries

**Key Point:** Benefits are real but limited; realistic counselling essential.

---

### 7. COMPLICATIONS & COUNSELLING (1 mark)

**Complications:**
- Ovarian hyperstimulation syndrome (OHSS): 1-2% moderate; <0.2% severe
- Bleeding/infection at oocyte retrieval: <0.5%
- Osmotic damage during freezing/thawing: Rare if protocols followed
- Storage failure: <1% (if proper tank maintenance)

**Patient Counselling Points:**
1. Success depends on age **NOW** (not age when eggs are used)
2. Only 28% live birth rate overall
3. Most women (89%) never use their frozen oocytes
4. Multiple costs: retrieval, storage, thawing, IVF
5. Set realistic expectations; not a guarantee of pregnancy
6. Alternative options: adoption, child-free life, donor oocytes

**Key Point:** Informed consent requires transparent discussion of limited success and psychological burden.

---

## QUICK SUMMARY FOR EXAM

| Concept | Answer |
|---------|--------|
| **Definition** | Freezing mature eggs for future fertility preservation |
| **Best technique** | Vitrification (ultra-rapid freezing) |
| **Survival rate** | 78.5% post-thaw |
| **Live birth rate** | 28% overall (52% if age ≤35) |
| **Age effect** | Critical factor; younger = better |
| **Storage duration** | Indefinite at -196°C |
| **Return rate** | Only 11% use their oocytes |
| **Main complication** | OHSS (<2%), storage costs |

---

## ALTERNATE 7-MARK QUESTION FORMAT

**Q: Compare vitrification and slow freezing of oocytes. What are the current recommendations?**

**Answer Structure:**

1. **Definition of vitrification** - Ultra-rapid freezing (~20,000°C/min), glass-like state, minimal ice crystals
2. **Definition of slow freezing** - Gradual controlled freezing (1-2°C/min), more water extrusion time
3. **Vitrification advantages** - Fast (<15 min), high survival (78%), reproducible, now standard
4. **Slow freezing advantages** - Lower cryoprotectant toxicity, established technique, comparable outcomes
5. **Meta-analysis comparison** - No statistical difference in survival (RR 0.96, p=0.52), follicle viability, DNA fragmentation
6. **Current recommendation** - Vitrification preferred (ASRM, ESHRE guidelines)
7. **Clinical implication** - Choice between techniques not critical; outcomes equivalent, vitrification faster and practical

**Total: 7 marks**

---

## ANOTHER 7-MARK QUESTION FORMAT

**Q: Discuss planned oocyte cryopreservation (POC) for social freezing. What are the success rates and ethical considerations?**

**Answer Structure:**

1. **Definition** - Elective freezing of oocytes by women without infertility to delay motherhood
2. **Success rate** - 28% live birth per patient overall
3. **Age stratification** - ≤35 years: 52%, 35-40 years: ~28%, ≥40 years: 19%
4. **Oocyte survival** - 78.5% post-thaw
5. **Low return rate** - Only 11% of women actually use frozen oocytes
6. **Counselling points** - Realistic expectations, high costs, psychological burden, alternative options
7. **Ethical considerations** - Patient autonomy vs. unrealistic expectations, resource allocation, informed consent requirements

**Total: 7 marks**

---

## ANOTHER 7-MARK QUESTION FORMAT

**Q: What are the indications for oocyte cryopreservation in oncology patients? Discuss timing and outcomes.**

**Answer Structure:**

1. **Medical urgency** - Before chemotherapy/radiotherapy that will damage ovarian reserve
2. **Cancer types** - Hematologic malignancies (leukemia, lymphoma), breast cancer, Hodgkin lymphoma
3. **Time constraint** - Must complete retrieval within 10-14 days before chemotherapy starts
4. **Ovarian stimulation** - Standard protocols; safety in hormone-sensitive malignancies varies
5. **Outcomes** - 78% oocyte survival post-thaw; pregnancy rates similar to non-cancer population
6. **Counselling** - Must discuss during treatment planning; psychological impact; realistic expectations
7. **Key advantage** - Preserves option of biological children; does not delay cancer treatment

**Total: 7 marks**

---

## EXAM WRITING TIPS

**How to get 7/7 marks:**

1. **Define clearly** - Start with one-liner definition; saves time and shows understanding
2. **Use structured points** - Numbered or bulleted list (easier to grade, clearer for examiner)
3. **Include data/numbers** - Survival rates, success rates, statistics (shows evidence-based knowledge)
4. **Compare/contrast** - If asked about two techniques, explicitly compare them
5. **State current recommendations** - What is standard NOW (vitrification, ASRM/ESHRE guidelines)
6. **Discuss limitations** - Show critical thinking (low return rates, costs, age-dependent success)
7. **Mention counselling** - Ethical/informed consent aspects (examiners love this)

**What examiners mark:**
- Accuracy of facts
- Completeness (covered all aspects)
- Use of current evidence/guidelines
- Clinical relevance
- Clear communication

---

## COMMON 7-MARK EXAM QUESTIONS ON THIS TOPIC

1. **"Define oocyte cryopreservation and discuss its indications, techniques, and outcomes."** (Full coverage)
2. **"Compare vitrification and slow freezing. What is current practice?"** (Techniques)
3. **"What are the success rates and ethical issues with social freezing?"** (POC/elective)
4. **"Discuss oocyte cryopreservation in cancer patients before chemotherapy."** (Oncology)
5. **"What counselling points are essential before oocyte cryopreservation?"** (Counselling)
6. **"What are the complications and limitations of oocyte cryopreservation?"** (Safety/realism)
7. **"Compare oocyte cryopreservation with ovarian tissue cryopreservation."** (Comparative)

---

## KEY NUMBERS TO MEMORIZE FOR EXAMS

- **78.5%** = oocyte survival post-thaw
- **28%** = live birth rate (planned cryopreservation)
- **52%** = live birth rate if frozen at age ≤35
- **19%** = live birth rate if frozen at age ≥40
- **11%** = percentage of women who return to use frozen oocytes
- **~15 minutes** = time for vitrification procedure
- **8-15** = recommended number of mature oocytes
- **-196°C** = storage temperature (liquid nitrogen)
- **Indefinite** = storage duration possible
- **1-2%** = OHSS risk (moderate)

---

**Format:** 7-Mark Exam Answer  
**Time Allocation:** 10-12 minutes writing time (approximately)  
**Target:** MS3-MS4 / Resident Board Exams  
**Last Updated:** August 26, 2026